Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide West Nile Virus Infections - Pipeline Review, H2 2019, provides an overview of the West Nile Virus Infections (Infectious Disease) pipeline landscape.
West Nile infection is caused by a virus transmitted by mosquitoes. The West Nile virus is a type of virus known as a Flavivirus. Symptoms include a fever, headache, body aches, skin rash, and swollen lymph glands. Risk factors for developing a more severe form of West Nile virus include conditions that weaken the immune system, such as HIV, organ transplants, and recent chemotherapy, age and pregnancy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide West Nile Virus Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for West Nile Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The West Nile Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 4, 6, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively.
West Nile Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of West Nile Virus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for West Nile Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in West Nile Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates West Nile Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for West Nile Virus Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for West Nile Virus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding West Nile Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
West Nile Virus Infections - Overview
West Nile Virus Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
West Nile Virus Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
West Nile Virus Infections - Companies Involved in Therapeutics Development
AIM ImmunoTech Inc
CEL-SCI Corp
Emergex Vaccines Ltd
Ennaid Therapeutics LLC
Fab’entech SA
Hawaii Biotech Inc
Imutex Ltd
Kineta Inc
Najit Technologies Inc
Plex Pharmaceuticals Inc
West Nile Virus Infections - Drug Profiles
AGS-v - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGS-v PLUS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alferon LDO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide for West Nile Virus Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BG-323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETX-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBV-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HydroVax-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-n3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTX-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Flavivirus Serine Protease for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NS2B-NS3 Protease for Dengue, West Nile Virus and Zika Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tatbeclin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
West Nile virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WNV-86 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
West Nile Virus Infections - Dormant Projects
West Nile Virus Infections - Product Development Milestones
Featured News & Press Releases
Nov 20, 2018: Vanderbilt discovery could neutralize West Nile virus
Feb 21, 2017: hVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate
Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials
May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro
Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena
Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for West Nile Virus Infections, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: West Nile Virus Infections - Pipeline by AIM ImmunoTech Inc, H2 2019
Table 11: West Nile Virus Infections - Pipeline by CEL-SCI Corp, H2 2019
Table 12: West Nile Virus Infections - Pipeline by Emergex Vaccines Ltd, H2 2019
Table 13: West Nile Virus Infections - Pipeline by Ennaid Therapeutics LLC, H2 2019
Table 14: West Nile Virus Infections - Pipeline by Fab’entech SA, H2 2019
Table 15: West Nile Virus Infections - Pipeline by Hawaii Biotech Inc, H2 2019
Table 16: West Nile Virus Infections - Pipeline by Imutex Ltd, H2 2019
Table 17: West Nile Virus Infections - Pipeline by Kineta Inc, H2 2019
Table 18: West Nile Virus Infections - Pipeline by Najit Technologies Inc, H2 2019
Table 19: West Nile Virus Infections - Pipeline by Plex Pharmaceuticals Inc, H2 2019
Table 20: West Nile Virus Infections - Dormant Projects, H2 2019
Table 21: West Nile Virus Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019
List of Figures
Figure 1: Number of Products under Development for West Nile Virus Infections, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Targets, H2 2019
Figure 5: Number of Products by Stage and Targets, H2 2019
Figure 6: Number of Products by Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
